[{"data":1,"prerenderedAt":163},["ShallowReactive",2],{"drug-epoprostenol":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":19,"formulations":23,"regimens":38,"contraindications":59,"warnings":69,"renal":77,"monitoring":78,"interactions":79,"review":80,"examples":83,"atc":84,"iran":86,"usApproval":106,"links":112,"populations":128},"epoprostenol",1,{"fa":7,"en":8},"اپوپروستنول","Epoprostenol","blood",{"fa":11,"en":12},"پروستاسیکلین","Prostacyclin",[14,17],{"name":15,"market":16},"Flolan","US",{"name":18,"market":16},"Veletri",[20,21,22,7],"flolan","veletri","فلولان",[24],{"id":25,"form":26,"route":27,"label":28,"concentration":29,"markets":33,"refs":34},"vial-1-5","powder-for-injection","iv","1.5 mg vial (also 0.5 mg)",{"amount":30,"unit":31,"perUnit":32},1.5,"mg","vial",[16],[35],{"source":36,"section":37},"fda-epoprostenol","3",[39],{"id":40,"disease":41,"label":42,"population":45,"type":49,"unit":31,"dose":50,"refs":54},"pah","pulmonary-arterial-hypertension",{"fa":43,"en":44},"PAH (WHO گروه ۱) — انفوزیون وریدی مداوم از کاتتر مرکزی؛ شروع ۲ نانوگرم\u002Fkg\u002Fدقیقه","PAH (WHO group 1) — continuous IV infusion via central catheter; start 2 ng\u002Fkg\u002Fmin",{"minAge":46},{"value":47,"unit":48},18,"year","notCalculated",{"reason":51},{"fa":52,"en":53},"هر ۱۵ دقیقه یا بیشتر ۲ نانوگرم\u002Fkg\u002Fدقیقه افزایش تا حد تحمل؛ تنظیم مزمن با گام‌های ۱ تا ۲. فقط با آب استریل یا سالین بازسازی؛ با داروی دیگر مخلوط نشود. قطع یا کاهش ناگهانی ممنوع (برگشت علائم، مرگ).","Increase by 2 ng\u002Fkg\u002Fmin every ≥15 min to tolerance; chronic adjustments in 1–2 ng\u002Fkg\u002Fmin steps. Reconstitute only with sterile water or saline; do not mix with other drugs. Avoid abrupt withdrawal or large reductions (rebound, death).",[55,57],{"source":36,"section":56},"2.1",{"source":36,"section":58},"2.2",[60],{"id":61,"severity":62,"text":63,"refs":66},"chf","block",{"fa":64,"en":65},"مصرف مزمن در نارسایی قلب ناشی از اختلال شدید سیستولیک بطن چپ؛ بروز ادم ریه در شروع دارو؛ حساسیت به دارو.","Chronic use in heart failure due to severe left ventricular systolic dysfunction; pulmonary oedema during dose initiation; hypersensitivity.",[67],{"source":36,"section":68},"4",[70],{"text":71,"refs":74},{"fa":72,"en":73},"افت فشار و برافروختگی در شروع؛ علائم برگشتی با قطع؛ عفونت کاتتر؛ خونریزی (مهار پلاکت).","Hypotension and flushing at initiation; rebound symptoms on withdrawal; catheter infection; bleeding (platelet inhibition).",[75],{"source":36,"section":76},"5",[],[],[],{"status":81,"reviewer":82,"date":82},"unverified",null,[],[85],"B01AC09",{"status":87,"forms":88,"refs":101},"registered",[89,93,97],{"code":90,"en":91,"fa":92},"06744","EPOPROSTENOL 500MCG VIAL","ویال اپوپروستنول ۵۰۰ میکروگرم",{"code":94,"en":95,"fa":96},"52165","EPOPROSTENOL (AS SODIUM) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION PARENTERAL 0.5 mg","محلول تزریقی اپوپروستنول (معادل سدیم) ۰٫۵ میلی‌گرم",{"code":98,"en":99,"fa":100},"52166","EPOPROSTENOL (AS SODIUM) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION PARENTERAL 1.5 mg","محلول تزریقی اپوپروستنول (معادل سدیم) ۱٫۵ میلی‌گرم",[102],{"source":103,"section":104,"url":105},"darooyab-generic","G-3181\u002FEpoprostenol","https:\u002F\u002Fwww.darooyab.ir\u002FG-3181\u002FEpoprostenol",{"kind":107,"refs":108,"id":111},"ANDA",[109],{"source":36,"section":110},"SPL approval \u002F marketing category","ANDA219237",[113,116,120,123,126],{"kind":114,"url":115,"label":111},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=219237",{"kind":117,"url":118,"label":119},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=47f64fcd-cbf7-457a-9548-661fb10ff7e0","FDA Epoprostenol",{"kind":121,"url":122,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa622042.html",{"kind":124,"url":125,"label":85},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=B01AC09",{"kind":127,"url":105,"label":8},"darooyab",{"pregnancy":129,"lactation":138,"pediatric":146,"geriatric":155},{"level":130,"text":131,"quote":134,"refs":135},"caution",{"fa":132,"en":133},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Limited published data from case series and case reports with Epoprostenol for Injection have not established a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes when used during pregnancy.",[136],{"source":36,"section":137},"8.1",{"level":130,"text":139,"quote":142,"refs":143},{"fa":140,"en":141},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of epoprostenol in either human or animal milk, the effects on the breastfed infant, or the effect on milk production.",[144],{"source":36,"section":145},"8.2",{"level":147,"text":148,"quote":151,"refs":152},"not-established",{"fa":149,"en":150},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[153],{"source":36,"section":154},"8.4",{"level":130,"text":156,"quote":159,"refs":160},{"fa":157,"en":158},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.",[161],{"source":36,"section":162},"8.5",1792444396661]